logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 7943728 B1

PDFFull Text
Date of Patent:
May. 17, 2011

Filed:

Dec. 20, 2007

Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases

Applicants:

Woei-jer Chuang, Tainan, TW;

Wen-mei Fu, Taipei, TW;

Tur-fu Huang, Taipei, TW;

Wenya Huang, Tainan, TW;

Chih-hsin Tang, Miaoli County, TW;

Chiu-yueh Chen, Tainan, TW;

Inventors:

Woei-Jer Chuang, Tainan, TW;

Wen-Mei Fu, Taipei, TW;

Tur-Fu Huang, Taipei, TW;

Wenya Huang, Tainan, TW;

Chih-Hsin Tang, Miaoli County, TW;

Chiu-Yueh Chen, Tainan, TW;

Assignees:

National Cheng Kung University, Tainan, TW;

National Taiwan University, Taipei, TW;

Attorney:

Wood, Phillips, Katz, Clark & Mortimer

Primary Examiner:

Robert Landsman

Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 38/04 (2006.01); C07K 2/00 (2006.01); C07K 4/00 (2006.01); C07K 5/00 (2006.01); C07K 7/00 (2006.01); C07K 14/00 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01); C12P 21/06 (2006.01); C12P 15/00 (2006.01); C12N 15/74 (2006.01); A01N 37/18 (2006.01);
U.S. Cl.
CPC ...
Abstract

Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin αvβ3 receptor-antagonist activity and substantially reduced integrin αllbβ3 and/or α5β1 receptor-blocking activity as compared to a wild-type disintegrin. The variant is encoded by a modified disintegrin nucleotide sequence that encodes a modified amino acid sequence, resulting in a polypeptide having substantially reduced affinity to integrin αllbβ3 and/or α5β1 as compared to a wild-type disintegrin. The variant is useful for treatment and/or prevention of αvβ3 integrin-associated diseases in a mammal, which include osteoporosis, bone tumor or cancer growth, angiogenesis-related tumor growth and metastasis, tumor metastasis in bone, malignancy-induced hypercalcemia, angiogenesis-related eye diseases, Paget's disease, rheumatic arthritis, and osteoarthritis. The angiogenesis-related eye diseases include age-related macular degeneration, diabetic retinopathy, corneal neovascularizing diseases, ischaemia-induced neovascularizing retinopathy, high myopia, and retinopathy of prematurity.

Find Patent Forward Citations

Loading…